INTERVACC AB revenue for the last year amounted to 8.00 M SEK, the most of which — 9.68 M SEK — came from its highest performing source at the moment, Novel Veterinary Vaccines, the year earlier bringing 5.24 M SEK. The greatest contribution to the revenue figure was made by Sweden — last year it brought INTERVACC AB 9.68 M SEK, and the year before that — 5.24 M SEK.